Form 8-K Arcus Biosciences, Inc. For: Jul 16

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Form 8-K Arcus Biosciences, Inc. For: Jul 16

Arcus Biosciences (RCUS) Chief Medical Officer Move to Gilead (GILD) Suggests Strengthened Relationship Between the Companies - Mizuho

July 20, 2021 6:47 AM EDT

Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $43.00 price target on Arcus Biosciences (NYSE: RCUS) after it was announced the transition of Chief Medical Officer - William "Bill" Grossman M.D., Ph.D. - to senior vice president of oncology at GILD overseeing... More

Arcus Biosciences (RCUS) Chief Medical Officer Grossman to Leave for Gilead (GILD)

July 19, 2021 5:10 PM EDT

Arcus Biosciences (NYSE: RCUS) announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gileads clinical-stage oncology portfolio. This will include leading Gileads efforts in the companys alliance with Arcus to co-develop and co-commercialize... More